Arcutis Biotherapeutics, Inc.
NasdaqGS ARQT
Arcutis Biotherapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -7.95
-
Arcutis Biotherapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -1.30 on January 19, 2024, which is 83.67% above the current Price to Earnings Ratio (P/E).
-
Arcutis Biotherapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -9.56 on January 07, 2025, which is -20.24% below the current Price to Earnings Ratio (P/E).
-
Arcutis Biotherapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -5.32.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Mr. Todd Franklin Watanabe M.A. |
| IPO Date | Jan. 31, 2020 |
| Location | United States |
| Headquarters | 3027 Townsgate Road |
| Employees | 296 |
| Sector | Health Care |
| Industries | |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Past 5 years
USD 1.44
USD 1.93
USD 5.56
USD 1.51
USD 4.57
USD 43.32
USD 27.69
USD 11.16
USD 1.56
USD 4.02
USD 3.13
StockViz Staff
January 15, 2025
Any question? Send us an email